Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.

Authors :: Sweeney DA
Tuyishimire B
Ahuja N
Beigel JH
Beresnev T
Cantos VD
Castro JG
Cohen SH
Cross K
Dodd LE
Erdmann N
Fung M
Ghazaryan V
George SL
Grimes KA
Hynes NA
Julian KG
Kandiah S
Kim HJ
Levine CB
Lindholm DA
Lye DC
Maves RC
Oh MD
Paules C
Rapaka RR
Short WR
Tomashek KM
Wolfe CR
Kalil AC
Source :: Open forum infectious diseases [Open Forum Infect Dis] 2023 Apr 19; Vol. 10 (5), pp. ofad205. Date of Electronic Publication: 2023 Apr 19 (Print Publication: 2023).
Publication Year :: 2023
Abstract: We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.<br />Competing Interests: Potential conflicts of interest. All authors: No reported conflicts.<br /> (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Full Text Access

Tools